Mariana Luiza Silva

Mrs. Mariana Luiza Silva

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2023 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MFMarciéli Fabris
Marciéli Fabris
MSMariana Luiza Silva
Mariana Luiza Silva
KSKaio Maciel de Santiago-Silva
Kaio Maciel de Santiago-Silva
MBMarcelle de Lima Ferreira Bispo
Marcelle de Lima Ferreira Bispo
PCPriscila Goes Camargo
Priscila Goes Camargo
CYP1B1 plays an essential role in cancer's pathogenesis since it activates procarcinogens. Significantly, this enzyme catalyzes the hydroxylation of 17β-estradiol, leading to carcinogenic metabolites involved in carcinogenesis and cancer progression. Therefore, the inhibition of CYP1B1 activity is considered a therapeutic target for chemotherapy. In addition, CYP1B1 is overexpressed in hormone-dependent cancer cells and could be related to resistance to anticancer drugs. However, the activity of CYP1B1 in the tumor microenvironment can metabolize and activate prodrugs in cancer cells, providing more selectivity and being useful for chemoprevention or chemotherapy strategies. Furthermore, due to its importance in anticancer drug design, recent studies have reported using computational methods to understand the intermolecular interactions between possible ligands and CYP1B1. Therefore, in this perspective, we highlight recent findings in developing CYP1B1 inhibitors (flavonoids, trans-stilbenes, estradiol derivatives, and carbazoles) and CYP1B1-activated prodrugs (a chalcone DMU-135 and an oxime DMAKO-20). Finally, we have analyzed their possible molecular interactions with this enzymatic target by molecular docking, which can help to design new active substances.

29 March 2025 in Plants
Verified
Journal Article
Open access
PDF file
GCGuilherme Ferreira Correia
Guilherme Ferreira Correia
CACamila Antunes
Camila Antunes
CVCamila Cristina Valentim
Camila Cristina Valentim
LSLais Fernanda de Almeida Spoladori
Lais Fernanda de Almeida Spoladori
HSHelena Tiemi Suzukawa
Helena Tiemi Suzukawa
SYSueli Fumie Yamada-Ogatta
Sueli Fumie Yamada-Ogatta
Since ancient times, plants have been used in folk medicine to treat different diseases. Plants offer exceptional chemical diversity with a wide range of biological activities, and have therefore been the most promising sources for the discovery and development of drugs, including antimicrobial agents. This study reports the antibacterial effect of geraniol (GER), alone and in combination with biogenic silver nanoparticles (bioAgNPs), produced using the aqueous extract of Trichilia catigua bark, against planktonic and sessile cells of methicillin-resistant Staphylococcus aureus (MRSA), one of the main opportunistic and potentially fatal human pathogens. GER had a time-dependent bactericidal effect on planktonic cells, impairing the cell membrane integrity. In addition, GER inhibited the staphyloxanthin production, and molecular docking analyses supported the in silico affinity of GER to dehydrosqualene synthase (CrtM) and 4,4′-diaponeurosporen-aldehyde dehydrogenase (AldH), which are key enzymes within the pigment biosynthesis pathway in S. aureus. GER treatment increased the sensitivity of MRSA to hydrogen peroxide killing. GER displayed synergism with bioAgNPs against planktonic and sessile cells, inhibiting bacterial adhesion and the viability of biofilms formed on abiotic surfaces. MRSA planktonic and sessile cells treated with GER or GER/bioAgNPs displayed severe morphological and ultrastructural alterations. Notably, neither GER nor its combination caused in vitro and in vivo toxicity in mammalian cells and Galleria mellonella larvae, respectively. These findings suggest that the combination of GER/bioAgNPs may be a promising strategy to control MRSA infections.

1 August 2023 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
MSMariana Luiza Silva
Mariana Luiza Silva
KSKaio Maciel de Santiago-Silva
Kaio Maciel de Santiago-Silva
MFMarciéli Fabris
Marciéli Fabris
PCPriscila Goes Camargo
Priscila Goes Camargo
MBMarcelle de Lima Ferreira Bispo
Marcelle de Lima Ferreira Bispo
Some diseases caused by trypanosomatid parasites, like Leishmaniasis, Chagas Disease, and Human African Trypanosomiasis (HTA), are challenging to manage, mainly concerning pharmacological therapy because they are associated with vulnerable populations. Unfortunately, there is a lack of significant investments in the search for new drugs. Therefore, one of the strategies to aid the discovery of new drugs is to identify and inhibit molecular targets essential to the parasite's survival, such as the proteasome, which degrades most proteins in the parasite cells. Our study has presented several proteasome inhibitors with various pharmacophoric cores, and two of them, 5, and 13, have stood out in the clinical phase of treatment for leishmaniasis.

1 September 2024 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
VMVinicius de Melo Milani
Vinicius de Melo Milani
MSMariana Luiza Silva
Mariana Luiza Silva
PCPriscila Goes Camargo
Priscila Goes Camargo
MBMarcelle de Lima Ferreira Bispo
Marcelle de Lima Ferreira Bispo
Tuberculosis (TB) remains a primary global health concern, necessitating the discovery and development of new anti-TB drugs, mainly to combat drug-resistant strains. In this context, thiourea derivatives have emerged as promising candidates in TB drug discovery due to their diverse chemical structures and pharmacological properties. This review aimed to explore this potential, identifying and exploring molecular targets for thiourea derivatives in Mycobacterium tuberculosis (Mtb) and the potential application of virtual screening techniques in drug discovery. We have compiled a comprehensive list of possible molecular targets of thiourea derivatives in Mtb. The enzymes are primarily involved in the biosynthesis of various cell wall components, including mycolic acids, peptidoglycans, and arabinans, or targets in the branched-chain amino acid biosynthesis (BCAA) pathway and detoxification mechanisms. We discuss the potential of these targets as critical constituents for the design of novel anti-TB drugs. Besides, we highlight the opportunities that virtual screening methodologies present in identifying potential thiourea derivatives that can interact with these molecular targets. The presented findings contribute to the ongoing efforts in TB drug discovery and lay the foundation for further research in designing and developing more effective treatments against this devastating disease.

1 January 2024 in Journal of the Brazilian Chemical Society
Verified
Journal Article
Closed access
MFMarciéli Fabris
Marciéli Fabris
PCPriscila Goes Camargo
Priscila Goes Camargo
MSMariana Luiza Silva
Mariana Luiza Silva
TSTalis Silva
Talis Silva
SMSergio de Paula Machado
Sergio de Paula Machado
MBMarcelle de Lima Ferreira Bispo
Marcelle de Lima Ferreira Bispo
In this report, we designed and synthesized ten N-(R-phenyl)-3-carboxamide-coumarin derivatives (2a-2j), exploring the coumarin nucleus, and an R-phenyl group as a structural scaffold and a peptide bond as a linker between them. The structure-activity relationships were investigated with different R-substituents (H, Br, NO2, Cl) in ortho, meta, or para positions from the phenyl group. Coumarins were obtained in good yields (72-95%), and in vitro screening against Canavalia ensiformis urease showed potential inhibitory percentages ranging from 42 to 65%. Half-maximal inhibitory concentration (IC50) values were determined for the best compounds 2b (R = 2-Br) and 2d (R = 4-Br). After conducting molecular docking and molecular dynamics on urease from C. ensiformis and Helicobacter pylori, potential binding modes for the most effective compounds 2b and 2d showed that these derivatives are able to interact with the crucial residue Cys592, thereby blocking the access of the urea substrate to the active site. According to density functional theory (DFT) calculations, 4-Br substitution on H. pylori urease was necessary for interacting with catalytic amino acids on the active site.

3 July 2026 in Chemico-Biological Interactions
Verified
Journal Article
Open access
MSMariana Luiza Silva
Mariana Luiza Silva
ANAngélica Paulina Nunes
Angélica Paulina Nunes
JCJoão Gabriel de Albuquerque Cavalcanti
João Gabriel de Albuquerque Cavalcanti
KSKaio Maciel de Santiago-Silva
Kaio Maciel de Santiago-Silva
PCPriscila Goes Camargo
Priscila Goes Camargo
MBMarcelle de Lima Ferreira Bispo
Marcelle de Lima Ferreira Bispo
Leishmaniases are a group of neglected tropical diseases caused by protozoan parasites of the genus Leishmania. The global incidence of these diseases is estimated to be between 700,000 and 1 million new cases per year. Given the concerns related to current antileishmanial drugs, such as parental administration and toxicity, the need for new alternative drugs is clear. In this context, arginase emerges as a potential molecular target for the discovery of novel inhibitors. Arginase is a manganese-dependent enzyme that catalyzes the production of polyamines from L-arginine, and its inhibition in Leishmania disrupts polyamine metabolism, which is essential for parasite survival and proliferation. Therefore, the present study employed a virtual screening strategy, including molecular docking, molecular dynamics (MD) simulations, and ADMET (absorption, distribution, metabolism, elimination, and toxicity) analysis, to identify potential inhibitors of Leishmania amazonensis arginase (LaARG) from an in-house chemolibrary of 66 compounds. The thiazolidinone LaSMMed47 emerged as the top hit, demonstrating strong interactions with Mn2+ ions at the catalytic site of LaARG. The structural stability of the LaSMMed47-LaARG complex was confirmed by MD simulations for 200 ns. Furthermore, ADMET predictions indicated that LaSMMed47 possesses favorable drug-likeness, high gastrointestinal absorption, and a low toxicity profile. Since LaSMMed47 is a previously unreported compound, it was synthesized in this study with a 64% yield; its structure and purity were confirmed through melting point, NMR (1H and 13C), IR, and HRMS analyses. The in vitro inhibition of bovine arginase by LaSMMed47 was evaluated by determining the percentage of inhibition (%I), which was 28.1%. Phenotypic in vitro assays also demonstrated the antileishmanial activity, with LaSMMed47 exhibiting an IC50 of 1.7 μM against promastigotes and 0.03 μM against intracellular amastigotes of L. amazonensis. Additionally, the compound demonstrated low toxicity in murine macrophages (CC50 > 100 μM), resulting in a high selectivity index for both developmental forms of the parasite. Together, these results indicate that thiazolidinones, particularly LaSMMed47, are promising chemical scaffolds for developing selective arginase inhibitors and new treatment options for leishmaniasis.